

Azathioprine Metabolite Levels and Outcomes During Pregnancies in Women with Rheumatic Disease

Supplemental Materials


Supplemental Figure S1 Ratio of 6-MMPN to 6-TGN throughout pregnancy and peripartum.



Supplemental Figure S2 Dose-adjusted 6-TGN and TPMT phenotype.




Supplemental Figure S3 Individual trajectories of AZA metabolite levels in patients without dose changes. Trimester 0 represents pre-pregnancy and Trimester 4 represents postpartum.



Supplemental Figure S4 SLE Physician Global Assessment and 6-TGN therapeutic category.

Grey area represents the interquartile range whereas the solid black line represents the median.



Supplemental Table 1: Dose changes in patients with elevated 6-MMPN.

Patient	6-MMPN	Medication Change
Number	pmol/8X10 ⁸ RBC	
1	6062	150 mg (1.9 mg/kg) -> No change
2	6022	150 mg (2.1 mg/kg) -> No change
2	5929	150 mg (2.1 mg/kg) -> 100 mg (1.4 mg/kg)
3	8308	Discontinue AZA 150 mg (1.2 mg/kg), start
		mycophenolate (postpartum)
4	7767	150 mg (2.3 mg/kg) -> No change
4	8955	150 mg (2.1 mg/kg) -> 100 mg (1.4 mg/kg)
5	12859	200 mg (1.8 mg/kg) -> 50 mg (0.5 mg/kg)
6	5758	150 mg (1.9 mg/kg) - > 125 mg (1.6 mg/kg)
7	7483	175 mg (2.3 mg/kg) -> No change
7	9303	175 mg (2.3 mg/kg) -> 150 mg (1.8 mg/kg)
8	7908	150 mg (1.6 mg/kg) -> 100 mg (1.1 mg/kg)
9	8433	100 mg (2.1 mg/kg) -> No change
10	13184	150 mg (1.5 mg/kg) -> 100 mg -> 50 mg (0.5 mg/kg)